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Probiotic supplementation in 
preterm infants does not affect the 
risk of retinopathy of prematurity: 
a meta-analysis of randomized 
controlled trials
Giacomo Cavallaro  1, Eduardo Villamor-Martínez2, Luca Filippi3, Fabio Mosca1 &  
Eduardo Villamor2
Retinopathy of prematurity (ROP) is a vascular disorder of the developing retina in preterm infants and 
is a leading cause of childhood blindness. Perinatal infection plays a pathogenic role in ROP. Probiotic 
supplementation reduces the risk of late onset sepsis (LOS) in preterm infants but it remains to be 
determined whether this reduction translates into a reduction of other complications. We conducted a 
systematic review and meta-analysis to evaluate the possible role of probiotics in altering the risk of ROP. 
Eleven randomized controlled trials (4250 infants; probiotics: 2121) were included in the meta-analysis 
that showed a significantly decreased rate of LOS with a risk ratio (RR) of 0.807 and a 95% confidence 
interval (CI) of 0.705 to 0.924 (P = 0.010; fixed effects model) but could not demonstrate a significant 
effect of probiotics on any stage ROP (RR 1.053, 95% CI 0.903 to 1.228, P = 0.508, 4 studies), or severe 
ROP (RR 0.841, 95% CI 0.666 to 1.063, P = 0.148, 9 studies). Meta-regression did not show any significant 
association between the RR for LOS and the RR for severe ROP. In conclusion, our results suggest that 
infection prevention by probiotics does not affect the risk of developing ROP in preterm infants.
Retinopathy of prematurity (ROP) is a vascular disorder of the developing retina in preterm infants and is a lead-
ing cause of childhood blindness1–7. ROP progresses in two phases. The first phase begins with delayed retinal vas-
cular growth after birth and partial regression of existing vessels, followed by a second phase of hypoxia-induced 
pathological vessel growth8. Low gestational age (GA), low birth weight (BW), and supplemental oxygen therapy 
following delivery have consistently been associated with ROP1–7. However, ROP is a multifactorial disease and 
multiple other modifiable clinical factors have been associated with an increased risk of ROP. These include, 
among others, hypoxia, hypercapnia, hyperglycaemia, exposure to blood transfusions, poor postnatal weight 
gain, and perinatal infection/inflammation1–6,9–14. While prevention of ROP would be best aimed at reducing 
preterm birth, postnatal preventive efforts are directed at reducing the other stressors that may lead to injury of 
the developing retinal vessels15.
In a very recent systematic review, Fang et al. analysed the effectiveness of oxygen saturation targeting, nutri-
tional interventions, blood transfusion management, and infection prevention on the incidence of ROP1. They 
found that lower oxygen saturation targets reduced the risk of developing any stage ROP and severe ROP but 
increased mortality. In addition, aggressive parenteral nutrition reduced the risk of any stage ROP but not severe 
ROP. Supplementation of vitamin A, E, or inositol and breast milk feeding were beneficial but the effect was not 
observed in randomized controlled trials (RCTs)1. Finally, when the authors analysed the literature on infection 
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prevention and its effect on the incidence of ROP, they only included studies on fluconazole prophylaxis of inva-
sive fungal infections because these studies were the only reporting sufficient numbers for quantitative analysis. 
Despite a reduced risk of invasive fungal infection, fluconazole prophylaxis had no significant effect on the risk 
of developing severe ROP1.
Experimental and clinical studies support the concept that modulation of intestinal microbiota in preterm 
infants may alter the risk of infection, and systemic inflammatory response syndrome either directly or through 
immune modulation16–18. Probiotic bacteria are live microbial supplements that colonize the gastrointestinal tract 
and potentially provide benefit to the host19–21. Recent meta-analyses showed that probiotic supplementation 
reduces the time to achieve full enteral feeding and the risk of developing necrotizing enterocolitis (NEC) as well 
as late onset sepsis (LOS) in preterm infants22–34. Therefore, probiotic supplementation can be considered as a 
method of infection prevention in this population. In addition, some probiotic strains may have antioxidant prop-
erties35. Interestingly, a number of RCTs of probiotic supplementation in preterm infants included data on ROP 
as secondary outcome. Nevertheless, systematic analysis regarding the possible effect of probiotics on preventing 
ROP is lacking. The objective of this systematic review and meta-analysis was to study the effect of probiotic sup-
plementation in the incidence of ROP in preterm infants.
Methods
A protocol was developed prospectively that detailed the specific objectives, criteria for study selection, the 
approach to assessing study quality, clinical outcomes, and statistical methodology. The study is reported accord-
ing to the PRISMA checklist36.
Data Sources and Search Strategies. A comprehensive literature search was undertaken using PubMed, 
EMBASE and CENTRAL (the Cochrane Central Register of Controlled Trials, The Cochrane Library) from their 
inception to March 1, 2016. The search terms used in the three databases were (probiotic(s) OR lactobacillus OR 
saccharomyces OR bifidobacterium OR streptococcus) AND (retinopathy of prematurity OR sepsis OR late onset 
sepsis). Language was not restricted. Additional strategies to identify studies included manual review of reference 
lists of key articles that fulfilled our eligibility criteria, use of the “related articles” feature in PubMed, use of the 
“cited by” tool in Google Scholar, and manual review of reference lists of meta-analyses on probiotics in preterm 
infants22–34,37,38.
Eligibility Criteria and Study Selection. Investigators were divided into two groups (E.V.-M./E.V. and 
G.C./L.F.). Both groups searched the literature independently and assessed the eligibility of trials for inclusion 
in the review. Disagreements were settled by discussion and, if necessary, the other author (F.M.) was consulted. 
All titles and abstracts of papers identified by the search strategy were screened for relevance. At this stage, only 
clearly non-relevant articles were excluded. Full copies of all potentially relevant papers were obtained and texts 
were screened to assess eligibility for inclusion. Studies were included if they were RCTs involving the use of 
probiotics in preterm infants (GA <37 weeks) and reported results on ROP. Studies were excluded if they did 
not meet all of these inclusion criteria. Studies were reviewed to ensure that study populations did not overlap by 
checking subject sources and study time-frame. Where two or more studies reported on the same population, the 
most recent study was preferentially used (provided it reported data on ROP) to avoid duplicate data.
Data Extraction and Assessment of Risk of Bias. The two groups of investigators extracted the data 
independently by using a data collection form designed for this review. Data extracted included: GA and BW of 
participants, patient inclusion criteria, study design (age at the first day of intervention, duration of interven-
tion, dosage, and type of probiotic), and outcomes of interest. We defined ROP as any stage ROP or severe ROP 
(including stage 3 or 4, surgical, and threshold ROP). The number of cases of ROP and the number of patients 
analysed in each treatment group of each trial were entered into the form. Data on LOS were also extracted.
Two reviewers (G.C. and E.V.) independently assessed risk of bias in each trial by using the Cochrane “Risk of 
Bias Assessment Tool”39. For each domain (allocation sequence, allocation concealment, blinding of participants 
and outcome assessors, incomplete outcome data, selective outcome reporting, and other potential sources of 
bias) the risk was assessed as low, high, or unclear. Potential discrepancies during the data extraction process and 
assessment of risk of bias were resolved by discussion and consensus among all reviewers.
Statistical Analysis. Studies were combined and analysed using comprehensive meta-analysis V 3.0 
software (Biostat Inc., Englewood, NJ, USA). A fixed-effects model (Mantel–Haenszel; M-H) was used. However, 
analysis using random effects model was also conducted to ensure that the results and conclusions were not 
influenced by the type of model used for the meta-analysis. Effect size was expressed as risk ratio (RR) and 95% 
confidence interval (CI). Statistical heterogeneity was assessed with the Cochran’s Q statistic and by the I2 statis-
tic, which is derived from Q and describes the proportion of total variation that is due to heterogeneity beyond 
chance40. An I2 value of 0% indicates no observed between-study heterogeneity, and large values show increasing 
between-study heterogeneity. The risk of publication bias was assessed by visual inspection of the funnel plot and 
using Egger test. To identify any study that may have exerted a disproportionate influence on the summary effect, 
we deleted studies one at a time. To explore differences between studies that might be expected to influence the 
effect size, we performed univariate random-effects meta-regression (method of moments)41,42. A probability 
value of less than 0.05 (0.10 for heterogeneity) was considered statistically significant.
Results
There was no substantial disagreement between the reviewers on articles for inclusion, data extraction, and risk 
of bias assessment. Based on the titles and abstracts of 1317 citations, we identified 58 potentially relevant studies, 
11 of which met the inclusion criteria43–53 (Figure 1, Table 1). Two additional studies54,55 met the inclusion criteria 
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but were excluded due to the presence of unclear or high risk of bias in more than three domains (Table 2). The 
main characteristics of the studies are shown in Table 1. The 11 studies included 4250 infants from which 2121 
infants received probiotics. Nine studies included very preterm (GA <32 weeks) and/or very low BW (<1500 g) 
infants44–49,51–53. One study included extremely low BW preterm infants (<1000 g)43. One study included larger 
preterm infants (GA <37 weeks and BW <2500 g)50. The included studies randomized infants to different prepa-
rations, times of initiation and duration of therapy (Table 1). Of the 11 included studies, 1044–53 (91%) were 
judged to have low risk of bias for the domain of “random sequence generation,” and 744–48,50,51 (64%) were con-
sidered to have low risk of bias for “allocation concealment.” Details of the risk of bias analysis are depicted in 
Table 2. Additional data on percentage of cesarean section, use of antenatal corticosteroids, antenatal antibiotics, 
maternal infection, preterm rupture of membranes (PROM), and use of exclusive maternal milk are shown in 
Supplementary Table 1.
Although not clearly specified in the studies, it was assumed that data on ROP referred to the eye with the 
higher disease severity. Four studies43,45,49,50 reported data on any stage ROP and neither the individual studies nor 
the meta-analysis could detect a significant effect of probiotic supplementation (RR 1.053, 95% CI 0.903 to 1.228, 
P = 0.508, Fig. 2). The use of a random effects model instead of a fixed effect model did not significantly affect the 
results of the meta-analysis (RR 1.053, 95% CI 0.903 to 1.228, P = 0.508). In sensitivity analyses, excluding one 
study at a time, the summary RR ranged from 1.025 (95% CI 0.864–1.217, P = 0.774), when the study of Al Hosni 
et al.43 was excluded, to 1.206 (95% CI 0.932–1.562, P = 0.155), when the study of Costeloe et al.45 was excluded. 
The study of Roy et al.50 included larger infants than the other 3 studies (Table 1). However, when this study was 
excluded overall results were not substantially affected (RR 1.036, 95% CI 0.886–1.212, P = 0.658). Publication 
bias for the outcome of any stage ROP was not assessed due to the low number of studies.
Nine studies43–48,51–53 reported data on severe ROP and neither the individual studies nor the meta-analysis 
could detect a significant effect of probiotic supplementation (RR 0.841, 95% CI 0.666 to 1.063, P = 0.148, Fig. 3). 
The use of a random effects model instead of a fixed effect model did not significantly affect the results of the 
meta-analysis (RR 0.844, 95% CI 0.666 to 1.070, P = 0.160). Neither inspection of the funnel plot nor formal 
assessment using Egger’s test showed any evidence of publication bias in this analysis (Fig. 4). In sensitivity analy-
ses, excluding one study at a time, the summary RR ranged from 0.808 (95% CI 0.634–1.029, P = 0.084), when the 
study of Al Hosni et al.43 was excluded, to 0.889 (95% CI 0.683–1.157, P = 0.380), when the study of Totsu et al.52  
was excluded. In addition, exclusion of the analysis of the 3 studies43,52,53 with an unclear risk of allocation 
concealment bias did not substantially affect the results of the meta-analysis (RR 0.849, 95% CI 0.633–1.138, 
Figure 1. PRISMA flow diagram of search strategy and study selection.
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P = 0.273). Finally, exclusion of the study of Dilli et al.47, which reported a lower rate of ROP than the other stud-
ies, did not significantly affect the effect size (RR 0.849, 95% CI 0.633–1.138, P = 0.273).
All the included studies reported data on LOS and, when pooled, we observed a significant reduction of this 
outcome in the probiotics group (RR 0.807, 95% CI 0.705 to 0.924, P = 0.010). This significant reduction of LOS 
with probiotics was also observed when the 9 studies43–48,51–53 reporting on severe ROP were pooled (RR 0.809, 
95% CI 0.692 to 0.946, P = 0.008). We performed meta-regression analyses (methods of moments) in order to 
investigate the possible correlation between the effect size for LOS and the effects size for severe ROP. As shown 
in Fig. 5, meta-regression could not detect a statistically significant correlation between the reduction in LOS 
produced by the probiotics and the effect size for severe ROP. In addition, meta-regression could not detect any 
significant effect of the type of probiotic on the effect size for severe ROP (Lactobacillus yes/no: coefficient −0.048, 
95% CI −0.587 to 0.473, P = 0.856; Bifidobacterium yes/no: coefficient 0.019, 95% CI −0.519 to 0.557, P = 0.945; 
multi-strain products yes/no: coefficient 0.141, 95% CI −0.635 to 0.354, P = 0.577).
Study
Inclusion 
criteria 
(BW and/
or GA)
Sample size
Intervention
Duration of 
intervention Primary outcome
ROP LOS
Probiotics Control Pr Co Pr Co
Al Hosni 201243 BW 501–1000 g
n = 50 GA: 
25.7 (1.4) 
BW: 778 
(138)
n = 51 
GA: 25.7 
(1.4) BW: 
779 (126)
L. rhamnosus + B. 
infantis vs. no 
probiotics
Once daily from the 
time of initiation of 
enteral feeds, until 
discharge or 34 wks 
PMA
% infants with weight 
<10th centile at 34 
wks PMA
Any 32/44 
Severe 8
Any 28/48 
Severe 4 13/50 16/51
Chou 201044 BW <1500 g
n = 153 GA: 
28.5 (2.3) 
BW: 1103 
(232)
n = 148 
GA: 28.5 
(2.3) BW: 
1097 
(231)
L. acidophilus + B. 
infantis vs. No 
probiotics
After d 7 of life, 
from the time of 
commencement of 
enteral feeds, until 
discharge
Death or 
neurodevelopmental 
impairment
Severe 9/153 Severe 15/148 21/153 30/148
Costeloe 201645 GA <31 wk
n = 650 GA: 
27.8 (2.5) 
BW: 1039 
(312)
n = 660 
GA: 27.9 
(2.6) BW: 
1043 
(317)
B. breve BBG-001 
vs. placebo
Commenced within 
48 h of birth, until 
36 wks PMA
≥ Stage 2 NEC, LOS, 
death
Any 160/600 
Severe 23
Any 161/605 
Severe 25 73/650 77/660
Demirel 201346
GA ≤32 
wk and 
BW 
≤1500 g
n = 135 GA: 
29.4 (2.3) 
BW: 1164 
(261)
n = 136 
GA: 29.2 
(2.5) BW: 
1131 
(284)
S. boulardii vs. no 
probiotic
Once daily from the 
time of initiation of 
enteral feeds, until 
discharge
NEC ≥ Stage 2 Severe 12/135 Severe 14/136 20/135 21/136
Dilli 201547
GA <32 
wk and 
BW 
<1500 g
n = 100 GA: 
28.8 (1.9) 
BW: 1236 
(212)
n = 100 
GA: 28.2 
(2.2) BW: 
1147 
(271)
B. lactis vs. placebo
From d 8 of life, 
once daily until 
discharge or a 
maximum of 8 wks
NEC ≥ Stage 2 Severe 0/100 Severe 3/100 8/100 13/100
Jacobs 201348
GA <32 
wk and 
BW 
<1500 g
n = 548 GA: 
27.9 (2.0) 
BW: 1063 
(259)
n = 551 
GA: 27.8 
(2.0) BW: 
1048 
(260)
B. infantis + S. 
thermophilus + B. 
lactis vs. placebo
From enteral feed 
≥6 mL/day until 
discharge or term 
corrected age.
LOS Severe 28/548 severe 30/551 72/548 89/551
Manzoni 200649 BW <1500 g
n = 39 GA: 
29.6 (5.0) 
BW: 1212 
(290)
n = 41 
GA: 29.3 
(4.0) BW: 
1174 
(340)
L. rhamnosus GG 
vs. no probiotic
From d 3 of life, 
for 6 wks or until 
discharge
Enteric fungal 
colonization Any 16/39 Any 18/41 19/39 22/41
Manzoni 200953 BW <1500 g
n = 151 GA: 
29.8 (2.8) 
BW: 1138 
(253)
n = 168 
GA: 29.5 
(3.2) BW: 
1109 
(269)
L. rhamnosus 
GG + lactoferrin vs. 
placebo
From d 3 of life, 
for 6 wks or until 
discharge
LOS Severe 13/151 Severe 19/168 7/151 29/168
Roy 201450
GA <37 
wk and 
BW 
<2500 g
n = 56 GA: 
32.0 (2.0) 
BW: 1192 
(341)
n = 56 
GA: 32.2 
(2.0) BW: 
1069 
(365)
L. acidophilus + B. 
longum + B. 
bifidum + B. lactis 
vs. placebo
Commenced 
within 72 h of birth 
for 6 wks or until 
discharge
Enteric fungal 
colonization Any 14/56 Any 10/56 31/56 42/56
Sari 201251
GA <33 
or BW 
<1500 g
n = 86 GA: 
29.7 (2.5) 
BW: 1241 
(264)
n = 88 
GA: 29.8 
(2.3) BW: 
1278 
(273)
L. sporogenes, vs. no 
probiotic
From first enteral 
feeds until discharge
Growth and 
neurodevelopment at 
18–22 months
Severe 5/86 Severe 4/88 24/86 19/88
Totsu 201452 BW <1500 g
n = 153 GA: 
28.6 (2.9) 
BW: 1016 
(289)
n = 130 
GA: 28.5 
(3.3) BW: 
998 (281)
B. bifidum vs. 
placebo
Commenced within 
48 h of birth and 
continued until 
discharge
Day when enteral feed 
exceeding 100 mL/
kg/d
Severe 20/153 Severe 25/130 6/153 10/130
Table 1. Characteristics of the included studies. BW: birth weight; GA: gestational age; Pr: probiotics Co: 
control; ROP: retinopathy of prematurity; LOS: late onset sepsis. Data of GA (weeks) and BW (grams) in the 
sample size column are expressed as mean (SD).
www.nature.com/scientificreports/
5SCIeNtIFIC REPoRts | 7: 13014  | DOI:10.1038/s41598-017-13465-2
Other potential moderator variables tested by meta-regression were duration (in weeks) of the supplementation 
with probiotics (coefficient 0.040, 95% CI −0.079 to 0.158, P = 0.515), supplementation with probiotics ≤7 weeks 
(yes/no; coefficient −0.315, 95% CI −0.832 to 0.203, P = 0.233), mean GA of the studied population (coefficient 
per week: −0.181, 95% CI −0.447 to 0.087, P = 0.185), mean BW of the studied population (coefficient per 100 g: 
−0.154, 95% CI −0.478 to 0.170, P = 0.351), total number of included infants (coefficient per 100 infants 0.016, 95% 
CI −0.040 to 0.071, P = 0.583), publication year (coefficient 0.017, 95% CI −0.092 to 0.126, P = 0.754), percent-
age of cesarean section (coefficient −0.028, 95% CI −0.027 to 0.021, P = 0.816), percentage of PROM (coefficient 
−0.004, 95% CI −0.048 to 0.040, P = 0.855), percentage of use of antenatal corticosteroids (coefficient 0.006, 95% CI 
−0.008 to 0.020, P = 0.390), and percentage of use of antenatal antibiotics (coefficient 0.001, 95% CI −0.021 to 0.019, 
P = 0.929). Due to the low number of studies reporting on maternal infection and percentage of use of exclusive 
maternal milk (Supplementary Table 1), meta-regression for these two moderators was not performed.
Discussion
Probiotic supplementation in preterm infants is one of the most studied interventions in neonatal medi-
cine16,19,26,29–34,56. However, to the best of our knowledge, this is the first meta-analysis assessing the effect of probi-
otics on the development of ROP. Despite a reduced risk of LOS, our study could not demonstrate any significant 
effect of probiotic supplementation on the risk of developing ROP. The validity of our meta-analysis is potentially 
compromised as the included trials were highly variable with regard to enrolment criteria (i.e., BW and GA), 
timing, dose, and formulation of probiotic used. Moreover, ROP was not the primary outcome in any of the trials 
and the definition of severe ROP varied among the studies. In addition, separate data on the population with the 
highest risk of ROP (i.e., extremely preterm or extremely low BW infants) could not be retrieved.
Study
Random 
Sequence 
Generation
Allocation 
Concealment
Blinding of 
Participants and 
Personnel
Blinding of 
Outcome 
Assessment
Incomplete 
Outcome 
Data
Selective 
Reporting
Other 
Bias
Al Hosni 2011 UR UR LR LR LR LR LR
Chou 2008 LR LR LR LR LR LR LR
Costaloe 2016 LR LR LR LR LR LR LR
Demirel 2013 LR LR LR LR LR LR LR
Dilli 2015 LR LR LR LR LR LR LR
Fujii 2006 UR UR HR UR LR UR UR
Jacobs 2013 LR LR LR LR LR LR LR
Manzoni 2006 LR UR LR LR LR LR LR
Manzoni 2009 LR UR LR LR LR LR LR
Roy 2014 LR LR LR LR LR LR LR
Saengtawesin 2014 UR UR HR HR LR LR UR
Sari 2012 LR LR LR LR LR LR LR
Totsu 2014 LR UR LR LR LR LR LR
Table 2. Assessment of the risk of bias of the studies. LR: low risk; UR: unclear risk; HR: high risk. The studies 
of Fujii et al. and Saengtsawesin et al. were excluded from the meta-analysis due to the presence of unclear or 
high risk of bias in more than three domains.
Figure 2. Forest plot: Probiotic supplementation and risk of any stage retinopathy of prematurity. Fixed effects 
model.
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Increased susceptibility to infections in the preterm infant is due to functional defects of both innate and 
adoptive immunity combined with prolonged hospitalization, and frequent need for invasive procedures57,58. 
As reviewed by Lee & Dammann3, the effects of infection and inflammation in the pathogenesis of ROP may be 
direct, indirect, or both. Proinflammatory cytokines may exert a direct effect on retinal angiogenesis or sensitize 
the developing retina to the effects of oxygen, or other stressors. On the other hand, the circulatory instability 
and fluctuation of oxygen saturation following sepsis may affect the retinal perfusion and lead to increased retinal 
injury, particularly during the second phase of pathological vessel growth.
Figure 3. Forest plot: Probiotic supplementation and risk of severe retinopathy of prematurity. Fixed effects model.
Figure 4. Funnel plot assessing publication bias for severe ROP.
Figure 5. Meta-regression of the relationship between the effects of probiotics on late onset sepsis and severe ROP.
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Despite the pathogenic role of sepsis in the development of ROP, there is very little literature published on 
reducing the risk of infection in preterm neonates and its effect on ROP incidence1. As mentioned in the intro-
duction, only the effect of fungal infection prophylaxis with fluconazole has been systematically analyzed1. Our 
study is the largest meta-analysis to date investigating the effects of a strategy of infection reduction on the devel-
opment of ROP. We expected that an intervention, such as probiotic supplementation, with proven efficacy in 
reducing LOS, would also affect the rate of ROP. In fact, when the 11 studies included in our meta-analysis were 
pooled, it was observed a reduction of the risk of LOS among the infants receiving probiotics (RR 0.81, 95% 
CI 0.71 to 0.92). Interestingly, this RR was very similar to the one reported by Rao et al. in their meta-analysis 
on probiotics and LOS (RR 0.86, 95% CI 0.78 to 0.94)26. It should be noted that the meta-analysis of Rao et al. 
included 37 RCTs (i.e., the 11 studies of the present meta-analysis plus 26 studies that did not report on ROP). 
Therefore, our sample of 11 studies appears to be representative of the effects of probiotics on LOS reduction in 
preterm infants.
We performed a meta-regression analysis in order to investigate whether the studies achieving a higher rate 
of protection against LOS also achieved a higher rate of protection against severe ROP. Meta-regression is a sta-
tistical technique which examines the relationship between continuous or categorical moderators and the size 
of effects observed in the studies41,42. Thus, meta-regression allows for the exploration of more complex ques-
tions than does traditional meta-analysis. In our study, meta-regression could not show any significant correla-
tion between the RR for LOS and the RR for severe ROP. This suggests that the reduction in sepsis rate did not 
translate into a reduction of ROP. Nevertheless, it should be taken into account that a robust conclusion from 
meta-regression would require a larger number of included studies41,42.
Since probiotic supplementation in RCTs is not a homogeneous intervention, the choice of probiotic strain(s) 
is crucial and meta-analyses may be misleading with the risk that generalized conclusions are erroneously 
extrapolated to other probiotics16,59. Furthermore it is unclear whether multi-strain products are more effective 
than single strain products16. Separate meta-analyses of the effects of well-defined individual, single strain or 
multiple-strain probiotic preparations appears to be more appropriate but the important heterogeneity of the 
RCTs makes this approach unfeasible16. In the present study, meta-regression could not detect any significant 
effect of the type of probiotic (Lactobacillus, Bifidobacterium or multi-strain products) on the effect size for severe 
ROP. Of note is that the largest trial published so far45 was negative for all clinical outcomes, including ROP, but 
the study product (B breve BBG-001) had never been reported to have any clinical effect in neonates59. Therefore, 
more studies to address the optimal probiotic preparation, dosing, and duration of therapy are still needed in head 
to head comparative studies rather than placebo controlled trials29. These studies should compare strains that 
have been reported to be safe and effective in previous trials59.
It has been suggested that the type of milk (human or formula) that infants receive modifies the effect of 
probiotics60,61. Interestingly, in a recent meta-regression analysis, Thomas et al. showed that the effectiveness of 
probiotics in reducing NEC was higher in cohorts with increased rates of exclusive human milk61. Unfortunately, 
most studies included in the present analysis lacked information on type of feeding and, therefore, we were not 
able to stratify by type of milk feeding. Besides the use of human milk, other prenatal and postnatal factors such 
as maternal infections, delivery mode (vaginal delivery vs. cesarean section), or antibiotic use may shape the 
initial bacterial inoculum of the newborn and further configure the microbiome during early life62,63. This may 
interfere with the effects of probiotics. Thomas et al. showed, through meta-regression, that probiotics were more 
effective in preventing NEC in cohorts where lower proportions of mothers received antenatal corticosteroids61. 
In contrast, the rate of cesarean section did not significantly correlate with the effect of probiotics on NEC61. The 
present meta-regression analysis could not demonstrate a significant correlation between the rate of antenatal 
corticosteroids, antenatal antibiotics, PROM, or cesarean section and the effect of probiotics on ROP. However, as 
mentioned above, our meta-regression is limited by the low number of studies.
The issue of whether it is time to change practice and adopt the use of probiotics as a standard of care in pre-
term infants remains a hot topic for neonatologists. While some advocate a change in practice based on significant 
reduction in time to achieve full enteral feeding, severe NEC, LOS, and all-cause mortality17,19,26,29,38,61, others 
have raised concerns about the methodology of many of the published and advocate for waiting until further 
data on efficacy and safety in extremely preterm infants are available16,62–65. The evidence summarized in this 
meta-analysis suggests that, despite being effective in reducing LOS, probiotic supplementation does not affect 
the incidence of ROP in preterm infants. Nevertheless, further studies addressing this issue are needed to confirm 
our findings66–68.
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